The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

COLL

Collegium Pharmaceutical, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Overall research band Weak
Quality Strong
Valuation Weak
Balance sheet Very weak
Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

Collegium Pharmaceutical, Inc. is a specialized pharmaceutical company focused on developing and marketing medications for pain management. Its main products include Xtampza ER, an extended-release oral oxycodone formulation designed with abuse-deterrent properties for patients with severe, long-term pain, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release tapentadol formulations. The company serves patients requiring daily, continuous opioid therapy for pain and generates revenue through the sale of these prescription medications. Collegium Pharmaceutical, Inc. is headquartered in Stoughton, Massachusetts.

The current research profile is Premium Growth, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Business quality is the strongest visible dimension. Check valuation before treating that strength as an investment conclusion.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC12.6%Model input; read with the evidence status and period context.
Operating margin24.0%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years29.6%Model input; read with the evidence status and period context.
FCF margin42.0%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.